Bacteriophage and nanotechnology in the management of COVID-19: A Review Article

Bacteriophage and nanotechnology in the management of COVID-19: A Review Article

An international panic has been sparked by the Covid-19 virus outbreak regarding our knowledge and preparedness against virus outbreaks and be calls whole scientific community to level up fight against this giant killer. Scientists are exhaustively testing already available drugs efficient associat...

Full description

Bibliographic Details
Main Authors:	Abdulrazzaq Zghair, comSumayah Kasim
Format:	Article
Language:	English
Published:	University of Thi-Qar 2022-12-01
Series:	مجلة علوم ذي قار
Subjects:	Antibody, Bacteriophage, Covid-19, Nanomedicine, SARS-CoV-2, Treatment
Online Access:	https://jsci.utq.edu.iq/index.php/main/article/view/900

Similar Items

The emerging significance of nanomedicine-based approaches to fighting COVID-19 variants of concern: A perspective on the nanotechnology’s role in COVID-19 diagnosis and treatment
by: Chandra Kant Singh, et al.
Published: (2023-01-01)

Nanotechnology and COVID-19: Prevention, diagnosis, vaccine, and treatment strategies
by: Sumeyra Ayan, et al.
Published: (2023-01-01)

Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-19
by: Angela E. Peter, et al.
Published: (2021-03-01)

Inactivation of Bacteriophage ɸ6 and SARS-CoV-2 in Antimicrobial Surface Tests
by: Sabine Poelzl, et al.
Published: (2023-08-01)

Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures
by: Jia Wang, et al.
Published: (2023-06-01)

Development of Coronavirus Treatments Using Neutralizing Antibodies
by: Saman Fouladirad, et al.
Published: (2021-01-01)

Localized delivery of nanomedicine and antibodies for combating COVID-19
by: Bin Tu, et al.
Published: (2023-05-01)

Nanotechnology as a Shield against COVID-19: Current Advancement and Limitations
by: Mahendra Rai, et al.
Published: (2021-06-01)

Could SARS-CoV-2 Have Bacteriophage Behavior or Induce the Activity of Other Bacteriophages?
by: Carlo Brogna, et al.
Published: (2022-04-01)

A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine
by: Jingen Zhu, et al.
Published: (2022-08-01)

Dysbiosis of gut microbiota in COVID-19 is associated with intestinal DNA phage dynamics of lysogenic and lytic infection
by: Aya Ishizaka, et al.
Published: (2025-01-01)

The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19
by: Xuzhen Qin, et al.
Published: (2021-02-01)

Phage therapy in the Covid-19 era: Advantages over antibiotics
by: Atif Khan, et al.
Published: (2022-01-01)

COVID-19 and the COVID-19 Vaccine in Japan—A Review from a General Physician’s Perspective
by: Hiroshi Kusunoki
Published: (2023-06-01)

COVID-19 Infection in Children and Infants: Current Status on Therapies and Vaccines
by: Giuseppina Malcangi, et al.
Published: (2022-02-01)

Nanomedicine for the Diagnosis and Therapy of COVID-19
by: Yingruo Wang, et al.
Published: (2021-11-01)

The Relevance of Monoclonal Antibodies in the Treatment of COVID-19
by: Anabel Torrente-López, et al.
Published: (2021-05-01)

Nanotherapeutic Approaches to Treat COVID-19-Induced Pulmonary Fibrosis
by: Shrey Kanvinde, et al.
Published: (2023-05-01)

A retrospective real-world study of early short-course remdesivir in non-hospitalized COVID-19 patients at high risk for progression: low rate of hospitalization or death, regardless of immunocompetence status
by: José Manuel Ramos-Rincón, et al.
Published: (2023-10-01)

Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies
by: Brandon J. Beddingfield, et al.
Published: (2021-11-01)

Serological differentiation between COVID-19 and SARS infections
by: Wan Ni Chia, et al.
Published: (2020-01-01)

Diving boldly into COVID‐19 contaminated wastewater: Eyes at nanotechnology‐assisted solutions
by: Hussein E. Al‐Hazmi, et al.
Published: (2023-06-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)

Before attributing impaired cognition in the elderly to COVID-19, all influencing factors must be considered
by: Josef Finsterer
Published: (2024-05-01)

Recent Chronology of COVID-19 Pandemic
by: Sazada Siddiqui, et al.
Published: (2022-05-01)

Neutralizing monoclonal antibodies for COVID-19 treatment and prevention
by: Juan Pablo Jaworski
Published: (2021-03-01)

Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study
by: Sean W. X. Ong, et al.
Published: (2022-03-01)

Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity
by: Maximilian Koblischke, et al.
Published: (2020-11-01)

Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19
by: Angela Chiereghin, et al.
Published: (2021-02-01)

Neutralizing antibody titers after COVID-19 vaccination
by: Safoora Shirani Shams Abadi, et al.
Published: (2024-11-01)

Progress of the COVID-19: Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum
by: Dan Liang, et al.
Published: (2022-12-01)

Nanotechnology‐facilitated vaccine development during the coronavirus disease 2019 (COVID‐19) pandemic
by: Ziqi Wang, et al.
Published: (2022-10-01)

Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes
by: Minghui Li, et al.
Published: (2024-12-01)

Criteria for judging the immune markers of COVID‐19 disease vaccines
by: Nan Lin, et al.
Published: (2022-03-01)

Development of an Enzyme-Linked Immunosorbent Assay (ELISA) for Accurate and Prompt Coronavirus Disease 2019 (COVID-19) Diagnosis Using the Rational Selection of Serological Biomarkers
by: Theano Lagousi, et al.
Published: (2021-10-01)

Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients
by: Bertram Flehmig, et al.
Published: (2020-11-01)

Low risk of serological cross-reactivity between dengue and COVID-19
by: Michele Spinicci, et al.
Published: (2020-08-01)

Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays
by: Jenni Virtanen, et al.
Published: (2021-05-01)

KG-COVID-19: A Framework to Produce Customized Knowledge Graphs for COVID-19 Response
by: Justin T. Reese, et al.
Published: (2021-01-01)

The Impact of SARS-CoV-2 Immune Status and Societal Restrictions in Controlling COVID-19 across the World
by: Jasmijn Stroo, et al.
Published: (2023-08-01)